Fig. 7
Downregulation of PAPSS1 increases ERα and E2 expression, mediating cisplatin resistance in EOC. A, B mRNA and Western blot expression levels of ESR1 and CCND1 in A2780 and SKOV3 cells with or without cisplatin (2 or 50 μM); **P < 0.01, ***P < 0.001 vs. untreated two cells. C, D mRNA and Western blot expression levels of ESR1 and CCND1 in siPAPSS1 and si-NC transfected A2780 and SKOV3 cells (**P < 0.01, ***P < 0.001 vs si-NC two cells). E The E2 level in cell supernatants in two siRNA cells compared to two si-NC cells with or without cisplatin (2 or 50 μM) examined by ELISA 24 h later. F After 24 h of transfection, cells were treated with cisplatin + E2 (1 nM) for 24 h. CCK-8 assay revealed the cisplatin IC50 in two siRNA cells as compared to two si-NC cells. G A2780 and SKOV3 cells were plated in 6-well plates 24 h before transfection. Two cells were transfected with ptk-ERE-luc and pRLCMV as an internal control. After 24 h of serum-free starvation, A2780 and SKOV3 cells were treated with vehicle, E2 (1 nM), cisplatin (2 or 50 μM), E2 (1 nM) + cisplatin (2 or 50 μM) for 24 h. Cell lysates were assayed for luciferase activity. Luciferase activity was normalized against Renilla luciferase using the pRLCMV control vector. The data shown represent the mean ± SD. *** P < 0.001. ** P < 0.01. *P < 0.05